Cornerstone Capital’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.57M | Buy |
7,856
+2,739
| +54% | +$542K | 0.16% | 59 |
|
|
2025
Q4 | $968K | Sell |
5,117
-70
| -1% | -$13.4K | 0.1% | 64 |
|
|
2025
Q3 | $919K | Sell |
5,187
-550
| -10% | -$81.8K | 0.09% | 65 |
|
|
2025
Q2 | $652K | Hold |
5,737
| – | – | 0.07% | 64 |
|
|
2025
Q1 | $603K | Sell |
5,737
-760
| -12% | -$85.9K | 0.06% | 68 |
|
|
2024
Q4 | $696K | Hold |
6,497
| – | – | 0.07% | 67 |
|
|
2024
Q3 | $650K | Hold |
6,497
| – | – | 0.06% | 75 |
|
|
2024
Q2 | $547K | Hold |
6,497
| – | – | 0.06% | 73 |
|
|
2024
Q1 | $475K | Sell |
6,497
-460
| -7% | -$33.9K | 0.05% | 74 |
|
|
2023
Q4 | $497K | Sell |
6,957
-547
| -7% | -$32.3K | 0.05% | 76 |
|
|
2023
Q3 | $450K | Sell |
7,504
-3,522
| -32% | -$232K | 0.05% | 73 |
|
|
2023
Q2 | $795K | Sell |
11,026
-2,489
| -18% | -$187K | 0.09% | 62 |
|
|
2023
Q1 | $994K | Sell |
13,515
-155
| -1% | -$11K | 0.12% | 55 |
|
|
2022
Q4 | $913K | Sell |
13,670
-11,088
| -45% | -$721K | 0.12% | 57 |
|
|
2022
Q3 | $1.33M | Hold |
24,758
| – | – | 0.19% | 49 |
|
|
2022
Q2 | $1.38M | Hold |
24,758
| – | – | 0.18% | 50 |
|
|
2022
Q1 | $1.74M | Buy |
24,758
+2,124
| +9% | +$154K | 0.19% | 49 |
|
|
2021
Q4 | $2.18M | Sell |
22,634
-1,031
| -4% | -$95.2K | 0.23% | 47 |
|
|
2021
Q3 | $2.06M | Hold |
23,665
| – | – | 0.24% | 45 |
|
|
2021
Q2 | $1.94M | Hold |
23,665
| – | – | 0.22% | 47 |
|
|
2021
Q1 | $2.25M | Sell |
23,665
-15,729
| -40% | -$1.49M | 0.27% | 44 |
|
|
2020
Q4 | $2.44M | Buy |
39,394
+24,302
| +161% | +$1.39M | 0.31% | 40 |
|
|
2020
Q3 | $897K | Buy |
15,092
+162
| +1% | +$11.1K | 0.13% | 46 |
|
|
2020
Q2 | $1.04M | Sell |
14,930
-1,469
| -9% | -$93.1K | 0.18% | 40 |
|
|
2020
Q1 | $744K | Sell |
16,399
-1,040
| -6% | -$58.9K | 0.15% | 38 |
|
|
2019
Q4 | $1.14M | Sell |
17,439
-98
| -0.6% | -$6.55K | 0.16% | 49 |
|
|
2019
Q3 | $1.09M | Sell |
17,537
-195
| -1% | -$12.2K | 0.17% | 47 |
|
|
2019
Q2 | $1.26M | Sell |
17,732
-13,211
| -43% | -$973K | 0.2% | 47 |
|
|
2019
Q1 | $2.43M | Sell |
30,943
-71,445
| -70% | -$5.41M | 0.4% | 42 |
|
|
2018
Q4 | $8.67M | Buy |
102,388
+1,085
| +1% | +$116K | 1.55% | 25 |
|
|
2018
Q3 | $17.3M | Sell |
101,303
-10,869
| -10% | -$1.64M | 2.64% | 21 |
|
|
2018
Q2 | $14.5M | Sell |
112,172
-8,604
| -7% | -$960K | 2.46% | 25 |
|
|
2018
Q1 | $12.4M | Sell |
120,776
-1,203
| -1% | -$119K | 2.05% | 26 |
|
|
2017
Q4 | $10.4M | Buy |
121,979
+7,504
| +7% | +$650K | 1.77% | 26 |
|
|
2017
Q3 | $9.72M | Buy |
114,475
+6,002
| +6% | +$475K | 1.7% | 27 |
|
|
2017
Q2 | $8.21M | Buy |
108,473
+1,837
| +2% | +$129K | 1.56% | 28 |
|
|
2017
Q1 | $7.04M | Buy |
106,636
+12,206
| +13% | +$803K | 1.38% | 33 |
|
|
2016
Q4 | $5.99M | Buy |
94,430
+7,503
| +9% | +$473K | 1.28% | 33 |
|
|
2016
Q3 | $5.54M | Sell |
86,927
-5,810
| -6% | -$427K | 1.2% | 33 |
|
|
2016
Q2 | $6.9M | Sell |
92,737
-5,875
| -6% | -$436K | 1.5% | 29 |
|
|
2016
Q1 | $6.59M | Sell |
98,612
-1,654
| -2% | -$101K | 1.45% | 29 |
|
|
2015
Q4 | $6.78M | Sell |
100,266
-890
| -0.9% | -$54.9K | 1.53% | 28 |
|
|
2015
Q3 | $5.41M | Buy |
101,156
+6,412
| +7% | +$389K | 1.35% | 30 |
|
|
2015
Q2 | $5.96M | Buy |
94,744
+52,890
| +126% | +$2.89M | 1.37% | 31 |
|
|
2015
Q1 | $2.01M | Buy |
41,854
+288
| +0.7% | +$11K | 0.52% | 35 |
|
|
2014
Q4 | $1.38M | Buy |
41,566
+7,270
| +21% | +$236K | 0.36% | 38 |
|
|
2014
Q3 | $1M | Buy |
34,296
+3,478
| +11% | +$115K | 0.28% | 40 |
|
|
2014
Q2 | $1.2M | Sell |
30,818
-2,845
| -8% | -$115K | 0.32% | 39 |
|
|
2014
Q1 | $1.41M | Sell |
33,663
-2,180
| -6% | -$90.9K | 0.4% | 37 |
|
|
2013
Q4 | $1.18M | Hold |
35,843
| – | – | 0.34% | 38 |
|
|
2013
Q3 | $968K | Sell |
35,843
-5,218
| -13% | -$147K | 0.3% | 42 |
|
|
2013
Q2 | $958K | Buy |
+41,061
| New | +$738K | 0.31% | 39 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Cornerstone Capital's LGND Position: Q1 2026 in Review
Cornerstone Capital increased its Ligand Pharmaceuticals (LGND) stake by 54% in Q1 2026, buying an estimated $542K and bringing the position to 7,856 shares worth $1.57M. The position accounts for 0.16% of the portfolio, ranked #59.
Cornerstone Capital first reported a position in LGND in Q2 2013 and has held it in 52 quarters since. The position peaked at $17.3M in Q3 2018. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Cornerstone Capital held 7,856 shares of Ligand Pharmaceuticals worth $1.57M as of Q1 2026.
- Cornerstone Capital bought 2,739 Ligand Pharmaceuticals shares in Q1 2026, an estimated $542K.
- Ligand Pharmaceuticals made up 0.16% of Cornerstone Capital's portfolio in Q1 2026, its #59 holding.
- Cornerstone Capital first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Cornerstone Capital's Ligand Pharmaceuticals position peaked at $17.3M in Q3 2018.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Cornerstone Capital's 13F filing for Q1 2026, filed 12 May 2026.